Luteinizing hormone and Alzheimer disease

“

Considerable amount of time and resources have been spent testing the hypothesis that estrogen deficiency is responsible for the AD development in elderly women. This hypothesis could not be validated because estrogen replacement therapy do not prevent either the cognitive decline or reduce the AD risk. These findings led to changing the focus to LH and explore the therapeutic benefits of decreasing its levels and/or blocking its actions. Other underlying risk factors such as, family history, life style factors, obesity, diabetes etc, are necessary for LH to induce the disease because not all elderly women, who have elevated LH levels, will develop the AD. LH may also have a causative role in the AD development in elderly men, as they also have an age dependent progressive increase and sustained elevation (perhaps less so than in elderly women) of LH levels.

”